<!DOCTYPE html>
<html lang="en">
<head>
  
  
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    
    <link rel="canonical" href="https://jzpero.github.io/mednotes/Critical%20Care/Mechanical%20Ventilation/Ventilator-Associated%20Pneumonia/">
    <link rel="shortcut icon" href="../../../img/favicon.ico">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
    <title>Ventilator-Associated Pneumonia and Hospital-Acquired Pneumonia - MedNotes</title>
    <link href="../../../css/bootstrap-3.3.7.min.css" rel="stylesheet">
    <link href="../../../css/font-awesome-4.7.0.css" rel="stylesheet">
    <link href="../../../css/base.css" rel="stylesheet">
    <link rel="stylesheet" href="../../../css/highlight.css">
    <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <script src="../../../js/jquery-3.2.1.min.js"></script>
    <script src="../../../js/bootstrap-3.3.7.min.js"></script>
    <script src="../../../js/highlight.pack.js"></script>
    
    <base target="_top">
    <script>
      var base_url = '../../..';
      var is_top_frame = false;
        
        var pageToc = [
          {title: "Ventilator-Associated Pneumonia and Hospital-Acquired Pneumonia", url: "#_top", children: [
              {title: "Microbiology", url: "#microbiology" },
              {title: "Diagnosis", url: "#diagnosis" },
              {title: "Differential", url: "#differential" },
              {title: "Antimicrobial Therapy", url: "#antimicrobial-therapy" },
              {title: "Duration of Therapy", url: "#duration-of-therapy" },
              {title: "De-escalation and Discontinuation", url: "#de-escalation-and-discontinuation" },
              {title: "References", url: "#references" },
          ]},
        ];

    </script>
    <script src="../../../js/base.js"></script> 
</head>

<body>
<script>
if (is_top_frame) { $('body').addClass('wm-top-page'); }
</script>



<div class="container-fluid wm-page-content">
  <a name="_top"></a>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Respiratory%20Mechanics/Airway%20Occlusion%20Pressure%20%28P0.1%29/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Respiratory%20Mechanics/Airway%20Occlusion%20Pressure%20%28P0.1%29/" class="btn btn-xs btn-link">
        Airway occlusion pressure (P0.1)
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Ventilator%20Modes%20and%20Strategies/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Ventilator%20Modes%20and%20Strategies/" class="btn btn-xs btn-link">
        Ventilator Modes and Strategies
      </a>
    </div>
    
  </div>

    

    <h1 id="ventilator-associated-pneumonia-and-hospital-acquired-pneumonia">Ventilator-Associated Pneumonia and Hospital-Acquired Pneumonia</h1>
<h2 id="microbiology">Microbiology</h2>
<p>See below for MRSA/PsA information. In addition, Atypical bacteria (e.g. <em>Mycoplasma</em>, <em>Chlamydiae</em>, <em><a href="../../../Infectious%20Diseases/Legionella%20Infection/">Legionella</a></em>) don't generally cause VAP.Â  Consequently, atypical coverage is generally <em>not</em> utilized. Anaerobic coverage for pulmonary infections is generally indicated <em>only</em> in the context of <a href="../../../Respirology/Pleural%20Diseases/Pleural%20Effusion/">empyema</a> or lung abscess.</p>
<h2 id="diagnosis">Diagnosis</h2>
<h3 id="clinical-picture">Clinical Picture</h3>
<ul>
<li>worsening oxygenation and compliance</li>
<li>chest infiltrates (CXR, CT, POCUS)</li>
<li>Neutrophilia and left shift, fever, sputum production</li>
</ul>
<h3 id="definitions">Definitions</h3>
<ul>
<li>There is no gold standard for the diagnosis of HAP or VAP.</li>
<li>HAP is defined as a pneumonia not incubating at the time of hospital admission and occurring 48 hours or more after admission.</li>
<li>VAP is defined as a pneumonia occurring &gt;48 hours after endotracheal <a href="../../Procedures/Intubation/">intubation</a>.</li>
</ul>
<h3 id="investigations">Investigations</h3>
<ul>
<li>sampling methods<ul>
<li>noninvasive sampling with semiquantitative cultures (endotracheal aspiration) are preferred over invasive sampling (bronchoscopic techniques)<ul>
<li>This is because bronchoscopy hasn't been shown to affect mortality or length of stay in VAP</li>
<li>Bronchoscopy probably warranted to exclude PJP/invasive pulmonary Aspergillosis if these are seriously on the differential (leukopenia, steroids, HIV, other immunosuppression)</li>
<li>Cutoffs for diagnostic threshold for VAP if invasive methods are used:<ul>
<li>Protected specimen brush (PSB) - 10^3 CFU/mL</li>
<li>BAL - 10^4 CFU/mL</li>
</ul>
</li>
</ul>
</li>
<li>nares swab for MRSA</li>
</ul>
</li>
<li>biomarkers<ul>
<li>CRP, PCT, etc are not routinely recommended in the decision to start antibiotic therapy</li>
</ul>
</li>
<li>blood cultures<ul>
<li>approximately 15% of patients with VAP are bacteremic</li>
<li>at least 25% of positive blood cultures in suspected VAP patients are from a nonpulmonary source</li>
</ul>
</li>
<li>Repeat imaging </li>
</ul>
<h2 id="differential">Differential</h2>
<p>Always thinking about these! Viral pneumonia, <a href="../../ARDS/Acute%20Respiratory%20Distress%20Syndrome/">ARDS</a>, atelectasis, pulmonary edema, aspiration pneumonitis, pulmonary embolism with infarction, interstitial lung disease (e.g. COP, AIP).</p>
<h2 id="antimicrobial-therapy">Antimicrobial Therapy</h2>
<h3 id="hospital-acquired-pneumonia">Hospital-Acquired Pneumonia</h3>
<ul>
<li>Suspected HAP - treat according to microbiology (taking into account local AMR) rather than empirically.<ul>
<li>recommend empiric coverage for Staph aureus - MSSA vs MRSA depends on risk factors (Se below)<ul>
<li>MSSA + broad spectrum coverage: pip-tazo, cefepime, levofloxacin, meropenem</li>
<li>MRSA coverage: vancomycin or linezolid</li>
</ul>
</li>
<li>recommend empiric GNB/PsA coverage<ul>
<li>double vs single depends on risk factors (See below for VAP)</li>
</ul>
</li>
</ul>
</li>
</ul>
<p><img alt="" src="../_attachments/Pasted%20image%2020221214204654.png" /></p>
<h3 id="ventilator-associated-tracheobronchitis">Ventilator-Associated Tracheobronchitis</h3>
<ul>
<li>Antibiotics are NOT recommended (Weak recommendation, low quality evidence)</li>
</ul>
<h3 id="ventilator-associated-pneumonia">Ventilator-Associated Pneumonia</h3>
<ul>
<li>empiric treatment is guided by local antibiogram and local known pathogens</li>
<li>in suspected VAP, recommend covering for <em>Staph aureus, Pseudomonas, and other GNB in all empiric regimens</em><ul>
<li>MRSA coverage if: risk factors for AMR, &gt;10-20% MRSA prevalence, and unknown MRSA prevalance. Use vancomycin or linezolid. Otherwise MSSA coverage.<ul>
<li>Empiric MSSA + broad spectrum coverage: pip-tazo, cefepime, levofloxacin, meropenem.</li>
<li>a negative nares MRSA PCR essentially means the risk of MRSA VAP is &lt;2% -- consider this a test of exclusion (NOT in guideline)</li>
</ul>
</li>
<li>Double Pseudomonal coverage recommended for: risk factors for AMR, &gt;10% resistance to the monotherapy, and unknown resistance prevalence (weak recommendation, low quality) Single Pseudomonal coverage otherwise.</li>
<li>Avoid aminoglycosides, colistin if possible</li>
</ul>
</li>
</ul>
<p><img alt="" src="../_attachments/Pasted%20image%2020221214201548.png" />
<img alt="" src="../_attachments/Pasted%20image%2020221214204603.png" /></p>
<h4 id="inhaled-antibiotic-therapy">Inhaled antibiotic therapy</h4>
<ul>
<li>If the patient has VAP due to GNB susceptible to only aminoglycosides or polymyxins (colistin, polymyxin B) then recommended to treat with BOTH inhaled and systemic antibiotics</li>
<li>It is reasonable to consider adjunctive inhaled antibiotic therapy as a treatment of last resort for patients who are not responding to intravenous antibiotics alone, whether the infecting organism is or is not multidrug resistant (MDR).</li>
</ul>
<h3 id="proven-mrsa-hapvap">Proven MRSA HAP/VAP</h3>
<p>Treat with vancomycin or linezolid.</p>
<h3 id="proven-pseudomonas-hapvap">Proven Pseudomonas HAP/VAP</h3>
<ul>
<li>Definitive treatment should be guided by resistance testing.</li>
<li>Aminoglycoside monotherapy is not recommended in any setting.</li>
<li>If the patient is stable, and the resistance profile is known, then treat with monotherapy with a susceptible agent.</li>
<li>If the patient is NOT stable (septic shock, high risk of death which is &gt;25%) even if the resistance profile is known, then consider combination therapy (2 antibiotics). Once the septic shock resolves, then step down to monotherapy.</li>
</ul>
<h3 id="proven-esbl-hapvap">Proven ESBL HAP/VAP</h3>
<ul>
<li>Definite treatment should be based on resistance profiles.</li>
</ul>
<h3 id="proven-acinetobacter-hapvap">Proven Acinetobacter HAP/VAP</h3>
<ul>
<li>Reminder: this is a SPICE-HAM (AmpC) bug</li>
<li>Treat with a carbapenem or amp/sulbactam if susceptible.</li>
<li>If only sensitive to polymyxins then treat with IV polymyxin (colistin, polymyxin B) + adjunct inhaled colistin (see above)</li>
<li>Tigecycline is recommended against</li>
<li>Adjunct rifampicin is not recommended in addition to colistin.</li>
</ul>
<h3 id="proven-carbapenem-resistant-pathogens">Proven Carbapenem-resistant pathogens</h3>
<ul>
<li>Generally treated with IV polymyxin + inhaled colistin</li>
</ul>
<h2 id="duration-of-therapy">Duration of Therapy</h2>
<ul>
<li>VAP: 7 days (as opposed to 8-15 days)</li>
<li>HAP: 7 days</li>
</ul>
<h2 id="de-escalation-and-discontinuation">De-escalation and Discontinuation</h2>
<ul>
<li>De-escalate antibiotics when appropriate (combination therapy --&gt; monotherapy, broad spectrum --&gt; targeted)</li>
<li>PCT levels + clinical criteria to guide discontinuation (PCT not available widely in Canada)</li>
</ul>
<h2 id="references">References</h2>
<ol>
<li><a href="https://academic.oup.com/cid/article/63/5/e61/2237650">2016 IDSA/ATS HAP/VAP Guidelines</a></li>
<li><a href="https://emcrit.org/ibcc/vap/">Ventilator Associated Pneumonia (VAP) - EMCrit Project</a></li>
</ol>

  <br>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Respiratory%20Mechanics/Airway%20Occlusion%20Pressure%20%28P0.1%29/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Respiratory%20Mechanics/Airway%20Occlusion%20Pressure%20%28P0.1%29/" class="btn btn-xs btn-link">
        Airway occlusion pressure (P0.1)
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Ventilator%20Modes%20and%20Strategies/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Ventilator%20Modes%20and%20Strategies/" class="btn btn-xs btn-link">
        Ventilator Modes and Strategies
      </a>
    </div>
    
  </div>

    <br>
</div>

<footer class="container-fluid wm-page-content">
  <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a> using <a href="https://github.com/gristlabs/mkdocs-windmill">Windmill</a> theme by Grist Labs.</p>
</footer>

</body>
</html>